Design and synthesis of melatonin receptors agonists and antagonists

Farmaco

Volumn 55, Issue 3, 2000, Pages 184-187

  Tarzia, Giorgio ^a   Diamantini, Giuseppe ^a   Mor, Marco ^b   Spadoni, Gilberto ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Agonists and antagonists; Design and synthesis; Melatonin receptors

Indexed keywords

MELATONIN; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; MELATONIN RECEPTOR AGONIST; MELATONIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MOUSE; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY;

ANIMALS; DRUG DESIGN; HUMANS; MELATONIN; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033943333     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(00)00017-3     Document Type: Article

References (40)

1. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12:1991;151-180.
2. Arendt J., Deacon S. Treatment of circadian rhythm disorders. Melatonin Chronobiol. Int. 14:1997;185-204.
3. Zhdanova I.V., Wurtman R.J., Lynch H.J., Ives J.R., Dollins A.B., Morabito C., Matheson J.K., Schomer D.L. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin. Pharmacol. Ther. (St. Louis). 57:1995;552-558.
4. Arendt J., Skene D.J., Middleton B., Lockley S.M., Deacon S. Efficacy of melatonin treatment in jet lag, shift work and blindness. J. Biol. Rhythms. 12:1997;604-617.
5. Oldani A., Ferini-Strambi L., Zucconi M., Stankov B., Fraschini F., Smirne S. Melatonin and delayed sleep phase syndrome: ambulatory polygraphic evaluation. NeuroReport. 6:1994;132-134.
6. Pappola M.A., Sos M., Omar R.A., Bick R.J., Hickson-Bick D.L.M., Reiter R.J., Efthimiopoulos S., Robakis N.K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer peptide. J. Neurosci. 17:1997;1683-1690.
7. Blask D.E., Wilson S.T., Zalatan F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res. 57:1997;1909-1914.
8. Lipartiti M., Franceschini D., Zanoni R., Gusella M., Giusti P., Cagnoli C.M., Kharlamov A., Manev H. Neuroprotective effects of melatonin. Adv. Exp. Med. Biol. 398:1996;315-321.
9. Takaki K.S., Mahle C.D., Watson A.J. Melatonergic ligands: pharmaceutical development and clinical applications. Curr. Pharm. Des. 3:1997;429-438.
10. Hagan R.M., Oakley N.R. Melatonin comes of age? Trends Pharmacol. Sci. 16:1995;81-83.
11. Dubocovich M.L. Melatonin receptors: are there multiple subtypes? Trends Pharmacol. Sci. 16:1995;50-56.
12. Reppert S.M., Weaver D.R., Godson C. Melatonin receptors step into light: cloning and classification subtypes. Trends Pharmacol. Sci. 17:1996;100-102.
13. Morgan P.J., Barrett P., Howell H.E., Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem. Int. 24:1994;101-146.
14. Ebisawa T., Karne S., Lerner M.R., Reppert S.M. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc. Natl. Acad. Sci. USA. 91:1994;6133-6137.
15. Reppert S.M., Weaver D.R., Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 13:1994;1177-1185.
16. 1b melatonin receptor. Proc. Nad. Acad. Sci. USA. 92:1995;8734-8738.
17. Mazzucchelli C., Pannacci M., Nonno R., Lucini V., Fraschini F., Stankov B.M. The melatonin receptor in the human brain: cloning experiments and distribution studies. Mol. Brain Res. 39:1996;117-126.
18. Dubocovich M.L., Cardinali D.P., Guardiola-Le Maitre B., Hagan R.M., Krause D.N., Sugden D., Vanhoutte P.M., Yocca F.D. The IUPHAR Compendium of Receptor Characterization and Classification. 1998;187-193 IUPHAR Media, London, UK.
19. Duranti E., Stankov B., Spadoni G., Duranti A., Lucini V., Capsoni S., Biella G., Fraschini F. 2-Bromomelatonin: synthesis and characterization of a potent melatonin agonist. Life Sci. 51:1992;479-485.
20. Spadoni G., Stankov B., Duranti A., Biella G., Lucini V., Salvatori A., Fraschini F. 2-Substituted 5-methoxy-N-acyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity. J. Med. Chem. 36:1993;4069-4074.
21. Mor M., Rivara S., Silva C., Bordi F., Plazzi P.V., Spadoni G., Diamantini G., Balsamini C., Tarzia G., Fraschini F., Lucini V., Nonno R., Stankov B.M. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive CoMFA study. J. Med. Chem. 41:1998;3831-3844.
22. Spadoni G., Balsamini C., Diamantini G., Di Giacomo B., Tarzia G., Mor M., Plazzi P.V., Rivara S., Lucini V., Nonno R., Pannacci M., Fraschini F., Stankov B.M. Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity and molecular modeling study. J. Med. Chem. 40:1997;1990-2002.
23. 2 melatonin receptors. Med. Chem. Res. 8:1998;487-498.
24. Sugden D., Chong N.W.S., Lewis D.F.V. Structural requirements at the melatonin receptor. Br. J. Pharmacol. 114:1995;618-623.
25. Jansen J.M., Copinga S., Gruppen G., Molinari E.J., Dubocovich M.L., Grol C.J. The high affinity melatonin binding site probed with conformationally restricted ligands. - Part I. Pharmacophore and minireceptor models Bioorg. Med. Chem. 4:1996;1321-1332.
26. Grol C.J., Jansen J.M. The high affinity melatonin binding site probed with conformationally restricted ligands. - Part II. Homology modeling of the receptor Bioorg. Med. Chem. 4:1996;1333-1339.
27. Sicsic S., Serraz I., Andrieux J., Brémont B., Mathé-Allainmat M., Poncet A., Shen S., Langlois M. Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study. J. Med. Chem. 40:1997;739-748.
28. Navajas C., Kokkola T., Poso A., Honka N., Gynther J., Laitinen J.T. A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor. Eur. J. Pharmacol. 304:1996;173-183.
29. 3H]dopamine release from retina. Eur. J. Pharmacol. 105:1984;193-194.
30. Dubocovich M.L. Luzindole (N-0774): a novel melatonin receptor antagonist. J. Pharmacol. Exp. Ther. 246:1988;902-910.
31. Garratt P.J., Jones R., Tocher D.A., Sugden D. Mapping the melatonin receptor. Part 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines. J. Med. Chem. 38:1995;1132-1139.
32. S. Copinga, G. Van Brummelen, W.J. Drijfhout, P.G. Tepper, C.J. Grol, A.S. Horn, M.L. Dubocovich, Synthesis and pharmacological evaluation of 4-aryl-2-amidotetralins: nonindolic melatonin-receptor agents, in: Proc. XIIIth Int. Symp. Med. Chem. (Paris, September 19-23, 1994).
33. Guardiola-Le Maitre B., Delagrange P. Melatonin analogues: from pharmacology to clinical application. Eur. J. Med. Chem. 30:1995;643s-651s.
34. 1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;365-375.
35. Davies D.J., Garratt P.J., Tocher D.A., Vonhoff S., Davies J., Teh M.C., Sugden D. Mapping the melatonin receptor. Part 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles. J. Med. Chem. 41:1998;451-467.
36. Leclerc V., Fourmaintraux E., Depreux P., Lesieur D., Morgan P., Howell H.E., Renard P., Caignard D.H., Pfeiffer D., Delagrange P., Guardiola-Le Maitre B., Andrieux J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. Bioorg. Med. Chem. 6:1998;1875-1887.
37. Tarzia G., Diamantini G., Di Giacomo B., Spadoni G., Esposti D., Nonno R., Lucini V., Pannacci M., Fraschini F., Stankov B.M. 1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues. J. Med. Chem. 40:1997;2003-2010.
38. 1 melatonin receptor partial agonists, antagonists, and putative inverse agonists. J. Med. Chem. 41:1998;3624-3634.
39. 1a receptor following stable transfection into NIH3T3 cells. Br. J. Pharmacol. 124:1998;485-492.
40. Cozzi B., Stankov B., Viglietti-Panzica C., Capsoni S., Aste N., Lucini V., Fraschini F., Panzica G.C. Distribution and characterization of melatonin receptor in the brain of the Japanese quail, Coturnix japonica. Neurosci. Lett. 150:1993;149-152.